Showing results (101-110 of 188) with videos related to
Sort By:
Pageof 19
Bone|January 1, 1988
Evaluation of salmon calcitonin treatment in bone metastases from breast cancer--a controlled trialC Blomqvist, I Elomaa, L Porkka, et al.European Urology|January 1, 1988
Aminoglutethimide for advanced prostatic cancer resistant to conventional hormonal therapyI Elomaa, T Taube, C Blomqvist, et al.European Journal of Cancer (Oxford, England : 1990)|November 27, 2001
Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatmentL Vehmanen, T Saarto, I Elomaa, et al.British Journal of Cancer|May 1, 1996
Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinomaC Blomqvist, L Risteli, J Risteli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administrationC Blomqvist, I Elomaa, P Rissanen, et al.Bone|March 1, 1994
Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancerT Taube, I Elomaa, C Blomqvist, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patientsT Saarto, C Blomqvist, M Välimäki, et al.Acta Oncologica (Stockholm, Sweden)|January 1, 1992
FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trialC Blomqvist, I Elomaa, P Rissanen, et al.British Journal of Cancer|April 20, 2001
The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancerT Saarto, L Vehmanen, I Elomaa, et al.British Journal of Cancer|January 1, 1997
Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogensT Saarto, C Blomqvist, M Välimäki, et al.Pageof 19